Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given a consensus recommendation of “Hold” by the six ratings firms that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $35.75.

A number of brokerages have recently weighed in on SNN. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 10th. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the company a “market perform” rating in a research note on Tuesday, October 14th. Finally, Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th.

Smith & Nephew SNATS Stock Performance

NYSE SNN opened at $34.68 on Monday. The business’s 50 day moving average is $33.21 and its two-hundred day moving average is $34.68. Smith & Nephew SNATS has a 12-month low of $23.91 and a 12-month high of $38.79. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60.

Hedge Funds Weigh In On Smith & Nephew SNATS

Large investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in Smith & Nephew SNATS by 16.7% during the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock worth $9,657,000 after buying an additional 48,784 shares during the period. Goldman Sachs Group Inc. increased its holdings in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares in the last quarter. Focus Partners Wealth raised its position in Smith & Nephew SNATS by 59.8% in the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock valued at $552,000 after purchasing an additional 7,277 shares during the period. Callan Family Office LLC purchased a new position in Smith & Nephew SNATS in the second quarter valued at about $250,000. Finally, Inspire Investing LLC acquired a new position in shares of Smith & Nephew SNATS during the second quarter worth about $223,000. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.